CDNA
CareDx Inc
$
15.010
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
16.460
Open
16.460
VWAP
15.02
Vol
1.55M
Mkt Cap
772.00M
Low
14.580
Amount
23.32M
EV/EBITDA(TTM)
--
Total Shares
52.19M
EV
655.96M
EV/OCF(TTM)
15.41
P/S(TTM)
2.80
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
103.64M
+19.57%
0.217
+117.5%
100.55M
+18.74%
0.203
+102.5%
102.37M
+18.24%
0.195
+8.33%
Estimates Revision
The market is revising Downward the revenue expectations for CareDx, Inc (CDNA) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by 14.58%.
Revenue Estimates for FY2025
Revise Downward
-0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-2.73%
In Past 3 Month
Stock Price
Go Up
+14.58%
In Past 3 Month
6 Analyst Rating
19.92% Upside
Wall Street analysts forecast CDNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDNA is 18.00 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
4 Hold
0 Sell
Moderate Buy
19.92% Upside
Current: 15.010
Low
14.00
Averages
18.00
High
22.00
19.92% Upside
Current: 15.010
Low
14.00
Averages
18.00
High
22.00
William Blair
Market Perform
initiated
2025-08-25
Reason
William Blair
Price Target
2025-08-25
initiated
Market Perform
Reason
William Blair initiated coverage of CareDx with a Market Perform rating and no price target. The firm says CareDx is a pure-play provider of solutions for transplant centers. While the shares will likely prove undervalued at current levels over the long term, a recently proposed local coverage decision impacting the company's testing services segment, which represent 75% of revenue, "clouds the near-term thesis," the analyst tells investors in a research note. Blair's analysis points to a fair value close to $20 per share.
BTIG
Buy
downgrade
$26 -> $22
2025-08-13
Reason
BTIG
Price Target
$26 -> $22
2025-08-13
downgrade
Buy
Reason
BTIG lowered the firm's price target on CareDx to $22 from $26 and keeps a Buy rating on the shares. The company delivered a roughly in-line Q2 and tightened its full-year guidance range, though the key to the earnings call was CareDx estimating the impacts of the recent Palmetto MolDx draft LCD, which proposes to limit reimbursement, the analyst tells investors in a research note.
BTIG
Mark Massaro
Buy
downgrade
$30 -> $26
2025-07-29
Reason
BTIG
Mark Massaro
Price Target
$30 -> $26
2025-07-29
downgrade
Buy
Reason
BTIG analyst Mark Massaro lowered the firm's price target on CareDx to $26 from $30 and keeps a Buy rating on the shares ahead of the Q2 earnings report. The firm is positive on the SMID cap diagnostics and specialty clinical lab group, but favors mostly the labs over tools companies, where there is a clear path of expansion in gross margins and lift in cash flow, the analyst tells investors in a research note.
Craig-Hallum
Buy
downgrade
$40 -> $26
2025-07-18
Reason
Craig-Hallum
Price Target
$40 -> $26
2025-07-18
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on CareDx to $26 from $40 and keeps a Buy rating on the shares. The firm notes CareDx closed down 38.5% on Thursday in the wake of an unfavorable proposed Local Coverage Determination for transplant testing. Craig-Hallum thinks the shares are substantially undervalued at the current price, even if the rule is finalized.
Nephron Research
Thomas DeBourcy
Hold
to
Buy
upgrade
$28
2025-07-09
Reason
Nephron Research
Thomas DeBourcy
Price Target
$28
2025-07-09
upgrade
Hold
to
Buy
Reason
Nephron Research analyst Thomas DeBourcy upgraded CareDx to Buy from Hold with a $28 price target.
Goldman Sachs
Matthew Sykes
Strong Buy
Maintains
$34 → $26
2025-04-17
Reason
Goldman Sachs
Matthew Sykes
Price Target
$34 → $26
2025-04-17
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for CareDx Inc (CDNA.O) is 21.33, compared to its 5-year average forward P/E of 40.11. For a more detailed relative valuation and DCF analysis to assess CareDx Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
40.11
Current PE
21.33
Overvalued PE
184.09
Undervalued PE
-103.88
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
45.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
168.73
Undervalued EV/EBITDA
-78.36
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
5.19
Current PS
16.53
Overvalued PS
9.58
Undervalued PS
0.79
Financials
Annual
Quarterly
FY2025Q3
YoY :
+20.72%
100.06M
Total Revenue
FY2025Q3
YoY :
-124.57%
2.58M
Operating Profit
FY2025Q3
YoY :
-122.61%
1.68M
Net Income after Tax
FY2025Q3
YoY :
-121.43%
0.03
EPS - Diluted
FY2025Q3
YoY :
+226.46%
35.38M
Free Cash Flow
FY2025Q3
YoY :
+3.94%
69.36
Gross Profit Margin - %
FY2025Q3
YoY :
+2507.69%
10.17
FCF Margin - %
FY2025Q3
YoY :
-118.68%
1.67
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.0M
USD
5
6-9
Months
1.9M
USD
8
0-12
Months
131.7K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.0M
USD
5
6-9
Months
1.9M
USD
8
0-12
Months
131.7K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CDNA News & Events
Events Timeline
2025-11-04 (ET)
2025-11-04
16:22:17
CareDx increases FY25 revenue forecast to $372M-$376M, surpassing consensus of $368.9M
2025-11-04
16:21:37
CareDx Announces Q3 Earnings Per Share of 28 Cents, Exceeding Consensus Estimate of 14 Cents
2025-10-27 (ET)
2025-10-27
07:11:18
CareDx names Jeffrey Teuteberg as its new chief medical officer.
Sign Up For More Events
Sign Up For More Events
News
4.0
11:45 AMBenzingaInsights from Three Analysts on CareDx
6.0
09:49 AMBenzingaBTIG Reaffirms Buy Rating on CareDx, Increases Price Target to $25
9.5
11-05NASDAQ.COMPost-Q3 Results: VCYT, RIGL, NPCE, CDNA, and FBLG Experience Significant After-Hours Gains
Sign Up For More News
People Also Watch
AUPH
Aurinia Pharmaceuticals Inc
13.950
USD
-3.46%
EFC
Ellington Financial Inc
13.780
USD
+0.80%
NX
Quanex Building Products Corp
13.020
USD
-2.69%
PFBC
Preferred Bank
90.490
USD
-0.73%
WEAV
Weave Communications Inc
6.660
USD
-1.48%
WOOF
Petco Health and Wellness Company Inc
3.140
USD
-1.88%
BBSI
Barrett Business Services Inc
34.950
USD
-14.17%
VSAT
Viasat Inc
35.490
USD
-6.41%
CARS
Cars.com Inc
11.090
USD
+6.53%
UP
Wheels Up Experience Inc
1.260
USD
+5.00%
FAQ
What is CareDx Inc (CDNA) stock price today?
The current price of CDNA is 15.01 USD — it has decreased -9.2 % in the last trading day.
What is CareDx Inc (CDNA)'s business?
What is the price predicton of CDNA Stock?
What is CareDx Inc (CDNA)'s revenue for the last quarter?
What is CareDx Inc (CDNA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CareDx Inc (CDNA)'s fundamentals?
How many employees does CareDx Inc (CDNA). have?